Avigen Inc.

Andrew A. Sauter is Chief Financial Officer and Acting President and CEO. Mr. Sauter was appointed Chief Financial Officer in February 2008, after having served as Vice President, Finance since January 2006. Mr. Sauter joined Avigen as Controller in November 1999. Mr. Sauter oversees the financial reporting obligations of Avigen and its information technology needs. From 1992 to 1999, Mr. Sauter worked for BankAmerica Corporation in a variety of positions, including most recently as a Vice President in the Capital Markets Finance organization. From 1989 to 1992, he worked for Ernst & Young LLP. Mr. Sauter is a certified public accountant and holds a B.A. degree in economics from Claremont McKenna College.

Christina Thomson, J.D., joined Avigen in February 2000 and was appointed Vice President, Corporate Counsel in June 2004. She has also served as our Chief Compliance Officer since March 2004 and Corporate Secretary since January 2005. Ms. Thomson is a registered patent attorney, and has managed significant growth in Avigen's patent portfolio over the last five years. Ms. Thomson also oversees the company's litigation and administrative patent proceedings, as well as contract administration. Prior to joining Avigen, Ms. Thomson worked as a patent attorney with the law firm Knobbe Martens Olson & Bear LLP in Newport Beach, California, as a patent agent with Madson & Metcalf, P.C. in Salt Lake City, Utah, and as a scientist for Myriad Genetic Laboratories. Ms. Thomson holds a J.D. from the University of Utah College of Law and an M.S. in biology from the University of Utah.

Mr. Michael Coffee joined Adamas Pharmaceuticals in 2009. He brings more than 30 years sales, marketing and senior management experience working with emerging as well as large pharmaceutical companies. Prior to Adamas he served as Chief Business Officer for Avigen, Inc. He co-founded the Alekta Group, LLC to provide a comprehensive range of pharmaceutical development consulting services. Mr. Coffee also held positions as President and Chief Operating Officer of Amarin Corporation plc and Amarin Pharmaceuticals Inc., President and Chief Operating Officer of Elan Pharmaceuticals, and President and Chief Operating Officer of Athena Neurosciences, Inc. Mr. Coffee was Vice President of Marketing & Sales for Miles Pharmaceuticals, the U.S. division of Bayer AG, and Vice President of Sales for USV Laboratories. He began his career with Sandoz Pharmaceuticals. Mr. Coffee received a BS in Biology from Siena College.

Kirk W. Johnson, Ph.D., is vice president, research and development. Prior to joining Avigen in early 2004, he was senior director, pharmacology and preclinical development and a member of the executive management team of Genesoft Pharmaceuticals. From 1991 through 2001, Dr. Johnson was employed in both protein and small molecule therapeutic R&D at Chiron Corporation and eventually served as director, pharmacology and preclinical research. Dr. Johnson was involved in creating IND-enabling programs and contributing to successful IND and NDA filings at Chiron and Genesoft. Aside from general pharmacology and other preclinical development responsibilities, he has led research and clinical development projects for diverse indications including neuropathic pain, hemophilia, antibacterials, diabetes, obesity, acute inflammation, and cardiovascular disease. Dr. Johnson earned a BS in toxicology from the University of California, Davis, and a PhD in pharmacology and toxicology from the Medical College of Virginia. He did postdoctoral fellowships studying the mechanism of action of IL-2 from 1986 to1989 with Dr. Kendall Smith at Dartmouth and from 1990 to 1991 with Dr. Marian Koshland at the University of California, Berkeley. He has published nearly 50 manuscripts and four U.S. patents.

John Prendergast, Executive Chairman and CEO, is a biopharmaceutical executive who has been involved in the financing and corporate development of early to mid-stage biotechnology companies over the past 15 years. He is a co-inventor of Antyra's Phenogenix and Proteome Panning? technology modules. He is a co-founder and currently serves on the boards of Avigen Inc., Palatin Technologies and Avax Technologies. From 1991-1996, Dr. Prendergast was Managing Director of the Castle Group, a New York-based merchant bank where he was responsible for the identification and evaluation of products and technologies for the formation and development of a range of venture start-ups. He is currently the President of SummerCloud Bay Inc., a consulting practice specializing in these activities.

Richard Wallace, BCom (Hons), joined as a director of the Company in March 2006. Richard is Senior Vice President of Global Commercial Strategy at GlaxoSmithKline and a member of their Research and Development Executive, Commercial Operations Committee and Product Management Board. Since joining GSK in 1992, Richard has performed a number of roles from Vice President Commercial (Canadian Pharmaceuticals), Vice President US Business Development, and Vice President Sales & Marketing (US Oncology and HIV). Richard has over the past 6 years in R&D led Global Clinical Development and Product Strategy roles in Neurosciences, expanding to all therapeutic areas of the GSK portfolio. Richard's experience prior to joining GSK includes 8 years with Bristol Myers Squibb and 7 years at Johnson & Johnson in assignments spanning marketing, sales, manufacturing and general management. Richard received BCom and BCom.Honors degrees from Rhodes University, South Africa.

Daniel Vapnek, PhD, is currently an adjunct professor at the University of California, Santa Barbara, and has played an influential role in biotechnology in both academics and industry. For 16 years, Dr. Vapnek was the head of research at Amgen, the world's largest biotechnology company. He joined Amgen in 1981 as the director of research when the company had 36 employees, and rose to senior vice president of research by 1988. When he retired in 1997, the company had more than 5,000 employees worldwide and revenues of $2.4 billion. While at Amgen, Dr. Vapnek worked closely with Philip Whitcome, PhD, Amgen's former director of strategic planning and also one of its first employees. Prior to joining Amgen, Dr. Vapnek held a number of positions at the University of Georgia and the Yale University School of Medicine. He was awarded both his BS (1963) and PhD (1968) by the University of Miami in Florida.

Dr. Whitcome served as Chief Executive Officer at Proteolix from the company's funding in December 2003 to December 2005. He had been the Chairman of the Board at Avigen since 1995 and was a Director at BioArray Solutions, NeuroMolecular Pharmaceuticals, and Agenesys, privately held biotechnology companies. Prior to this, he was President and CEO of Neurogen Corporation, from its founding in 1988 to 1993. From 1981 to 1988, Dr. Whitcome was at Amgen Inc., where he served as Director of Strategic Planning. Prior to joining Amgen, he served as Manager of Corporate Development for Medical Products at Bristol-Myers Squibb Co. and held research and marketing management positions with the Diagnostics Division of Abbott Laboratories. Dr. Whitcome received a Ph.D. in Molecular Biology from the University of California at Los Angeles, an M.B.A. from the Wharton School at the University of Pennsylvania, and a B.S. in Physics from Providence College.

Dr. Iwaki holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. He is also a visiting professor at the Nihon University School of Medicine, Kyushu University and the Tokyo Women's Medical School in Japan. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. He received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of 200 peer-reviewed publications and more than 40 books. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 20 years and is a board member of several biotechnology companies.